@inbook{3a33b9436e3248ab97b5817e44ef9352,
title = "Biosimilars: Are they really safe?",
abstract = "An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.",
keywords = "Adverse events, Biosimilars, Cancer, Regulatory approval",
author = "McKoy, {June M.} and Giles, {Francis Joseph}",
note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2019.",
year = "2019",
doi = "10.1007/978-3-319-43896-2_5",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "61--73",
booktitle = "Cancer Treatment and Research",
}
